PRO-Kinetic Energy Coronary Stent System
Biotronik AG · Decision date Jun 5, 2026
What did the FDA approve?
FDA records P160003/S024 as a supplement to PMA P160003, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jun 5, 2026.
FDA approval order statement
the introduction of a new production site for supply of the hypotube and a new hypotube extrusion process
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160003/S024
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik AG
- Product code
- MAF
- Decision code
- APPR
- Decision date
- Jun 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, CORONARY.
- Applicant
- Biotronik AG
- Product code
- MAF
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160003/S024 received
Application receipt date recorded by FDA.
P160003/S026 · Related supplement
PRO-Kinetic Energy Coronary Stent System
P160003/S022 · Related supplement
PRO-Kinetic Energy Coronary Stent System
P160003/S024 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P160003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PRO-Kinetic Energy Coronary Stent SystemP160003/S026 | Biotronik AG | PMA supplement | Apr 1, 2026 | FDA |
PRO-Kinetic Energy Coronary Stent SystemP160003/S022 | Biotronik AG | PMA supplement | Apr 15, 2026 | FDA |
Explore the linked device profile
Other records with product code MAF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Mar 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P160003/S024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

